Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 133

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Tissue‐specific mtDNA lesions and radical‐associated mitochondrial dysfunction in human hearts exposed to doxorubicin

Lebrecht, Dirk, Kokkori, Aikaterini, Ketelsen, Uwe‐Peter, Setzer, Bernhard, Walker, Ulrich A.·2005·The Journal of Pathology

Abstract

Doxorubicin causes a chronic cardiomyopathy. Although the exact pathogenesis is unknown, recent animal data suggest that somatically acquired alterations of mitochondrial DNA (mtDNA) and concomitant mitochondrial dysfunction play an important role in its onset. In this study, skeletal and myocardial muscles were examined from human autopsies. Compared to controls ( n = 8), doxorubicin‐exposed hearts ( n = 6) showed low absolute enzyme activity of mtDNA‐encoded nicotinamide adenine dinucleotide hydrogen dehydrogenase (NADH DH, 79% residual activity, p = 0.03) and cytochrome c oxidase (COX, 59% residual activity, p < 0.001), but not of succinate dehydrogenase (SDH), which is encoded exclusively by nuclear DNA. NADH DH/SDH and COX/SDH ratios were 37% ( p < 0.001) and 27% ( p < 0.001) of controls. Expression of the mtDNA‐encoded subunit II of COX was reduced (82%, p = 0.04), compared to its unchanged nucleus‐encoded subunit IV. MtDNA‐content was diminished (56%, p = 0.02), but the ‘common’ mtDNA‐deletion was increased (9.2‐fold, p = 0.004). Doxorubicin‐exposed hearts harboured numerous additional mtDNA rearrangements lacking direct repeats. They contained elevated levels of malondialdehyde (MDA) ( p = 0.006, compared to controls), which correlated inversely with the COX/SDH ratio ( r = −0.45, p = 0.02) and the mtDNA‐content ( r = −0.75, p = 0.002), and correlated positively with the levels of the ‘common’ deletion ( r = 0.80, p < 0.001). Doxorubicin‐exposed hearts also contained the highest levels of superoxide ( p < 0.001, compared to controls), which correlated negatively with the mtDNA‐encoded respiratory chain activities, such as the COX/SDH ratio ( r = −0.57, p = 0.02) and the NADH/SDH ratio ( r = −0.52, p = 0.04), as well as with the mtDNA content ( r = −0.69, p = 0.003), and correlated positively with the frequency of the ‘common’ deletion ( r = 0.76, p < 0.001) and the MDA levels ( r = 0.86, p < 0.001). Doxorubicin‐exposed hearts contained electron‐dense deposits within mitochondria. Hearts exposed to other anthracyclines ( n = 6) or skeletal muscle (all groups) had no mitochondrial dysfunction. Doxorubicin, unlike other anthracyclines, augments lipid peroxidation, induces mtDNA mutations and decreases mtDNA content in human hearts. These lesions have an impact on mitochondrial function and could be of importance in the pathogenesis of clinical cardiomyopathy. Copyright © 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/path.1863

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 38

  1. 10.1056/NEJM199809243391307 · DOI · Paper page
  2. 10.1016/S0378-4274(01)00329-0 · DOI · Paper page
  3. 10.1006/bbrc.1993.2135 · DOI
  4. 10.1016/0301-4622(90)80012-V · DOI · Paper page
  5. 10.1111/j.1432-1033.1987.tb13649.x · DOI
  6. 10.1161/01.CIR.0000093196.59829.DF · DOI · Paper page
  7. 10.1161/01.CIR.0000055318.09997.1F · DOI · Paper page
  8. 10.1016/0921-8734(92)90021-G · DOI · Paper page
  9. 10.1002/humu.1380030107 · DOI · Paper page
  10. 10.1016/0076-6879(95)60134-1 · DOI
  11. 10.1097/00002030-200211080-00009 · DOI · Paper page
  12. 10.1126/science.2711184 · DOI · Paper page
  13. 10.1016/S0076-6879(96)64038-5 · doi:10.1016/s0076-6879(96)64038-5
  14. 10.1016/S0076-6879(96)64032-4 · DOI
  15. 10.1038/sj.sc.3100660 · DOI
  16. 10.1161/01.RES.82.12.1298 · DOI · Paper page
  17. 10.1124/pr.56.2.6 · DOI · Paper page
  18. 10.1200/JCO.1999.17.10.3333 · DOI · Paper page
  19. 10.1016/0163-7258(90)90088-J · DOI · Paper page
  20. 10.1161/01.RES.86.9.960 · DOI · Paper page
  21. 10.1016/0921-8734(92)90028-N · DOI
  22. 10.1126/science.6093249 · DOI · Paper page
  23. 10.1093/mutage/18.1.25 · DOI
  24. 10.1093/hmg/11.3.317 · DOI
  25. 10.1097/00001573-200105000-00008 · DOI
  26. 10.1053/pcad.2003.3b · DOI
  27. 10.1002/(SICI)1097-4598(200001)23:1<80::AID-MUS10>3.0.CO;2-V · doi:10.1002/(sici)1097-4598(200001)23:1<80::aid-mus10>3.0.co;2-v
  28. Childs AC, 2002, Doxorubicin treatment in vivo causes cytochrome c release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl‐2:Bax ratio, Cancer Res, 62, 4592
  29. 10.1016/S0006-2952(01)00865-6 · doi:10.1016/s0006-2952(01)00865-6
  30. 10.2165/00002018-200022040-00002 · DOI · Paper page
  31. 10.1016/S0005-2728(99)00011-0 · DOI · Paper page
  32. 10.2165/00003495-199300452-00005 · DOI
  33. Torti FM, 1986, Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy, Cancer Res, 46, 3722
  34. Borchmann P, 1997, Idarubicin: a brief overview on pharmacology and clinical use, Int J Clin Pharmacol Ther, 35, 80
  35. 10.1200/JCO.1993.11.7.1264 · doi:10.1200/jco.1993.11.7.1264
  36. 10.1007/BF00252973 · doi:10.1007/bf00252973
  37. 10.1007/BF00262774 · DOI
  38. 10.1038/290457a0 · DOI · Paper page

Cited by

See all 133

Metadata

Authors
Lebrecht, D., Kokkori, A., Ketelsen, U., Setzer, B., & Walker, U. A.
Venue
The Journal of Pathology
Publisher
Wiley
Published
2005-11-08
Volume
207
Issue
4
Pages
436-444
ISSN
  • 0022-3417
  • 1096-9896
Cited by
133
References
3
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.